Recent Updates
Recently added Catalysts

bazedoxifene/conjugated estrogens

Phase 3

Menopause | Small molecule | Other |Pfizer, Inc.|Last Updated: Apr 8, 2014

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials2
Total Enrollment1,886
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00808132Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal OsteoporosisPHASE3 COMPLETED 1,886Jan 1, 2009Feb 1, 2011Apr 8, 2014178 United States, Argentina +10
NCT00396799Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal WomenPHASE1 COMPLETED -Nov 1, 2006Nov 1, 2006Mar 13, 2007 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percentage of Participants With Endometrial Hyperplasia at Month 12: Main Study
Month 12

Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. If both the pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted. Results were summarized for two definitions of hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia); definition 1: participants were considered to have a diagnosis of hyperplasia when the 3 pathologists disagreed but at least 1 pathologist determined hyperplasia; definition 2: participants were considered to have a diagnosis of hyperplasia if at least 2 of the 3 pathologists agreed on the diagnosis.

Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12: Osteoporosis Sub-Study
Baseline, Month 12

BMD measurements of the anteroposterior lumbar spine were acquired by using dual-energy x-ray absorptiometry (DXA) scans, twice at Month 12 for a subset of participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. Mean percentage change from baseline of the 2 readings were reported.

Pharmacokinetic measures of blood levels of endogenous estrogen hormones, conjugated estrogens and bazedoxifene.
Secondary Endpoints
Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 6: Osteoporosis Sub-Study
Baseline, Month 6
Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 6, 12: Osteoporosis Sub-Study
Baseline, Month 6, Month 12
Percentage of Participants With Cumulative Amenorrhea: Main Study
Day 1 up to Day 364
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1EXPERIMENTALbazedoxifene 20 mg/conjugated estrogens 0.45 mg
2EXPERIMENTALbazedoxifene 20 mg/conjugated estrogens 0.625 mg
3EXPERIMENTALbazedoxifene 20 mg
4ACTIVE_COMPARATORPrempro
5PLACEBO_COMPARATORPlacebo
Interventions
NameTypeDescription
bazedoxifene 20 mg/ conjugated estrogens 0.45 mgDRUGOne capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
bazedoxifene 20 mg/ conjugated estrogens 0.625 mgDRUGOne capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
bazedoxifene 20 mgDRUGOne capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mgDRUGOne capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
PlaceboDRUGOne capsule, placebo (over-encapsulated), once a day for one year.
bazedoxifene/conjugated estrogensDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — 64 Years
SexFEMALE
Healthy VolunteersNo
Study Sites178

Inclusion Criteria: * Generally healthy, postmenopausal women, aged 40 to 64 seeking treatment for menopausal symptoms * At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels \> 40 mIU/mL * Intact Uterus Exclusion Criteria: ...

Countries:United StatesArgentinaAustraliaChileColombiaDenmarkFinlandHungaryMexicoNew ZealandNorwayPoland
Unlock Eligibility Criteria